Mural Oncology plc (MURA)

3.7700 0.0000 (0.00%) At close: 04:00PM EDT

Mural Oncology plc

10 Earlsfort Terrace
Dublin D02 T380
Ireland
353 1 905 8020
https://www.muraloncology.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 119

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Caroline J. Loew Ph.D.	President, CEO & Director	303.29k	N/A	1971
Mr. Adam D. Cutler B.A.	CFO, Principal Financial Officer & Principal Accounting Officer	496.65k	N/A	1975
Dr. Vicki L. Goodman M.D.	Chief Medical Officer	578.34k	N/A	1971
Ms. Maiken Keson-Brookes	Chief Legal Officer	N/A	N/A	1973
Mr. Justin Levine	Head of Human Resources & VP of Human Resources	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Corporate governance

Mural Oncology plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.